ArticleFrontiers in oncology2026
A pretreatment 15-gene signature predicts non-pCR in response to neoadjuvant chemotherapy in breast cancer and reveals a pyruvate-
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In breast cancer (BC), neoadjuvant chemotherapy (NAC) improves surgical options, and pathologic complete response (pCR) predicts better outcomes. Patients with residual disease (non-pCR) have higher recurrence risk, yet robust pretreatment biomarkers remain limited. Objective: To develop a pretreatment transcriptomic predictor of non-pCR and connect the predictive signal to an interpretable metabolic-transcriptional-signaling mechanism with potential therapeutic actionability. Methods: Three Gene Expression Omnibus (GEO) pretreatment bulk-expression cohorts were analyzed (GSE25066, GSE20194, GSE32646). Differentially expressed genes (DEGs) were integrated and a least absolute shrinkage and selection operator (LASSO) logistic model (trained on GSE25066) generated a 15-gene risk score (RS), externally validated in GSE20194 and GSE32646. A hospital clinical cohort provided paired samples and serum metabolomics focusing on glycolysis-related metabolites. Functional assays and RNA-seq tested pyruvate effects and MET inhibition (capmatinib). Single-cell RNA-seq plus inferCNV was used to localize key signals and infer a regulatory axis. Results: The 15-gene RS showed consistent discrimination for non-pCR (AUC: 0.823 training; 0.809 and 0.876 validations). Non-pCR tumors exhibited enriched cell-cycle programs (E2F/G2M), inflammatory signaling (TNFα/NF-κB), and estrogen-response pathways. Multi-omics highlighted Conclusions: A pretreatment 15-gene RS enables risk stratification for NAC non-pCR, and mechanistic evidence supports a pyruvate-
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.